E815
TEAS SECTION 8 & 15 RECEIVED
09/06/2026
Voltar para busca
Dado oficial do USPTO
AMGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
AMGEN
ST13
US500000086834490Classe
5, 10, 35, 36, 41, 42, 44
Pedido
86834490
Registro
6080333
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
71
Atualização mais recente
10/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 35, 36, 41, 42, 44
Data de depósito
30/11/2015
Data de registro
16/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/06/2020
Última transação
10/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/01/1990
Primeiro uso no comércio
01/01/1990
Código do desenho
4
Tipo de titular
03
Localização do titular
Thousand Oaks, CA, US
Examinador
TOY, JOSHUA SPENCER JOLL
Unidade examinadora
N20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Amgen Inc.
Representantes
Elsa D. Lemoine Amgen Inc.
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 35Classe 36Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals for the treatment of cardiovascularcancerboneneurological nephrological and inflammation disease and disorders; pharmaceutical preparations for the treatment of anemiaankylosing spondylitisarthritiscancercardiovascular conditionscollection by leukopheresiseffects of myelosuppressive chemotherapyeffects of myelosuppressive doses of radiationglandular disordershormone disordershypercalcemiahyperparathyroidismhyperphosphatemiakidney disorders and diseasemigraineneutropeniaosteoporosisparathyroid disorderspsoriasisreduction of red blood cell transfusionsrenal disordersthrombocytopenia; prescription pharmaceuticals for the treatment of anemiaankylosing spondylitisarthritiscancercardiovascular conditionscollection by leukopheresiseffects of myelosuppressive chemotherapyeffects of myelosuppressive doses of radiationglandular disordershormone disordershypercalcemiahyperparathyroidismhyperphosphatemiakidney disorders and diseasemigraineneutropeniaosteoporosisparathyroid disorderspsoriasisreduction of red blood cell transfusionsrenal disordersthrombocytopenia; and pre-filled syringes and vials containing pharmaceutical preparations for the treatment of the aforementioned diseases and disorders and complications associated therewith
Classe 10
Drug delivery devices in the nature of drug delivery systems; drug delivery systems; injection device for pharmaceutical preparations; injectors for medical purposes in the nature of medical fluid injectors
Classe 35
Online wholesale services by direct solicitation by salespersons directed to end-users featuring pharmaceuticals; referral services in the field of treatment for cancerchemotherapy and pharmaceutical products in the nature of medical referrals; business administration of prescription drug co-payment programs; business administration of patient reimbursement programs; referral services in the field of co-pay assistance programs in the nature of providing insurance agent referrals; providing an online commercial information directory in the field of patient support featuring information regarding healthcare providerssites at which subcutaneous injections could be administered and retail pharmacies or specialty pharmacies where patients could obtain pharmaceutical preparations
Classe 36
Providing healthcare administrationproviding insurance verification and prior authorization services for others
Classe 41
Educational servicesdevelopment and dissemination of printed educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting seminars in the field of the use of prescription pharmaceutical products for medical disorders; educational and entertainment servicesproviding a motivational and educational speaker featuring information regarding medical disorders; training services in the field of patient support services relating to treatment of medical disorders; providing on-line electronic newsletters delivered by email in the field of the treatment of medical disorders
Classe 42
Pharmaceutical research and development services; biological research; chemical research; medical researchconducting clinical trials for others
Classe 44
Patient support services relating to the treatment of medical disordersproviding online information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services via a global computer network; providing health and medical information about medical disorders; information servicesproviding medical information to cancer patients; providing patient support services relating to cancer and cancer treatment in the nature of an Internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; providing information about bone health in patients with cancer by offering customized medical information and practical advice for communicating about bone health with healthcare providers; information servicesproviding medical consultancy and advisory services via a global computer network in the field of cancer-related bone health; providing medical information and patient support servicesproviding pharmaceutical advice and consultation in the nature of providing online information regarding bone healththe prevention of osteoporosis and the treatment and management of osteoporosis and bone diseasepharmaceutical preparations for the treatment of osteoporosis; medical report services in the nature of providing medical reports regarding patients being treated for osteoporosis and bone disease; providing medical consultancy and advisory services via a global computer network in the field of cancer treatment and chemotherapy; providing medical information and patient support servicespharmaceutical advice and consultation in the nature of providing online information regarding immune thrombocytopenic purpura; providing health and medical information about immune thrombocytopenic purpura; information servicesproviding medical information to immune thrombocytopenic purpura patients; patient support services relating to treatment of medical disordersproviding information to patients and families of patients in the field of administering medicationpatient medical information where patients can inquire about medical issues and procedures from medical personnel
Publicações
Histórico de despachos e eventos da marca no USPTO.
71 publicações encontradas
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
16/06/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
25/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/04/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/04/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
29/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/04/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/04/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/04/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
16/06/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/05/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
14/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/10/2019
GNRT
NON-FINAL ACTION E-MAILED
28/10/2019
CNRT
SU - NON-FINAL ACTION - WRITTEN
28/10/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/10/2019
IUAF
USE AMENDMENT FILED
10/10/2019
EISU
TEAS STATEMENT OF USE RECEIVED
10/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/04/2019
EX5G
SOU EXTENSION 5 GRANTED
03/04/2019
EXT5
SOU EXTENSION 5 FILED
28/03/2019
EEXT
SOU TEAS EXTENSION RECEIVED
28/03/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/03/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/03/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/09/2018
EX4G
SOU EXTENSION 4 GRANTED
07/09/2018
EXT4
SOU EXTENSION 4 FILED
07/09/2018
EEXT
SOU TEAS EXTENSION RECEIVED
07/09/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/08/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/08/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
16/03/2018
EX3G
SOU EXTENSION 3 GRANTED
15/03/2018
EXT3
SOU EXTENSION 3 FILED
13/03/2018
EEXT
SOU TEAS EXTENSION RECEIVED
13/03/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
13/09/2017
EX2G
SOU EXTENSION 2 GRANTED
12/09/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/09/2017
EXT2
SOU EXTENSION 2 FILED
31/08/2017
EEXT
SOU TEAS EXTENSION RECEIVED
31/08/2017
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
29/03/2017
EX1G
SOU EXTENSION 1 GRANTED
27/03/2017
EXT1
SOU EXTENSION 1 FILED
27/03/2017
EEXT
SOU TEAS EXTENSION RECEIVED
27/03/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/10/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/08/2016
PUBO
PUBLISHED FOR OPPOSITION
16/08/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/07/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/07/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
13/07/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
13/07/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
13/07/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
13/07/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/05/2016
GNFR
FINAL REFUSAL E-MAILED
11/05/2016
CNFR
FINAL REFUSAL WRITTEN
11/05/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/04/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/04/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/04/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/01/2016
GNRT
NON-FINAL ACTION E-MAILED
08/01/2016
CNRT
NON-FINAL ACTION WRITTEN
08/01/2016
DOCK
ASSIGNED TO EXAMINER
07/01/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/12/2015
NWAP
NEW APPLICATION ENTERED
03/12/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AMGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.